MedTrace Logo

IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex

NCT00747604 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1378

Last updated 2020-11-06

No results posted yet for this study

Summary

This project is a retrospective (beginning January 2006) and prospective patient registry program sponsored by Ipsen (formerly Tercica, Inc.). In collaboration with participating health care practitioners, the patient registry program is an observational study monitoring the long-term safety of patients treated with Increlex® (mecasermin \[rDNA origin\] injection). The IGFD (Increlex® Growth Forum Database) Registry is intended primarily to monitor the safety and efficacy of Increlex replacement therapy in children with growth failure.

Conditions

  • Primary Insulin-like Growth Factor-1 Deficiency

Interventions

BIOLOGICAL

mecasermin [rDNA origin] injection

As prescribed by the physician.

Sponsors & Collaborators

Principal Investigators

  • Medical Director, Endocrinology · Ipsen (formerly Tercica)

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00747604 on ClinicalTrials.gov